Wednesday, 14 October 2026European Markets

NEDAP And SOPRA STERIA GROUP Have A High Dividend Yield And Return On Equity In The Information Technology Services Industry.

Loading stream...

(vianews) - nedap (nedap.as) is among this list of stock assets with the highest dividend rate and return on equity on the information technology services industry.

financial asset price forward dividend yield return on equity
nedap (nedap.as) €57.00 5.26% 23.16%
sopra steria group (sop.pa) €198.90 2.34% 13.77%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. nedap (nedap.as)

5.26% forward dividend yield and 23.16% return on equity

nedap n.v., together with its subsidiaries, develops and supplies smart technological solutions in the netherlands, germany, rest of europe, north america, and internationally. the company provides software services that allow healthcare professionals to interconnect; hardware and software solutions for vehicle identification systems; and technological solutions for the dairy farming and pig farming industries. it also offers lighting solutions and uv lamp driver technologies; and rfid solutions for retailers. in addition, the company provides access control and security systems for companies and institutions. further, it offers workforce management software, a cloud-based software for timesheet processing, employee scheduling, and access control. the company was founded in 1929 and is headquartered in groenlo, the netherlands.

earnings per share

as for profitability, nedap has a trailing twelve months eps of €3.17.

pe ratio

nedap has a trailing twelve months price to earnings ratio of 17.98. meaning, the purchaser of the share is investing €17.98 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.16%.

moving average

nedap's worth is under its 50-day moving average of €57.44 and below its 200-day moving average of €57.15.

yearly top and bottom value

nedap's stock is valued at €57.00 at 12:40 est, way under its 52-week high of €63.70 and above its 52-week low of €52.60.

revenue growth

year-on-year quarterly revenue growth grew by 11.1%, now sitting on 230.56m for the twelve trailing months.

volume

today's last reported volume for nedap is 653 which is 74.7% below its average volume of 2582.

more news about nedap.

2. sopra steria group (sop.pa)

2.34% forward dividend yield and 13.77% return on equity

sopra steria group sa provides consulting, digital, and software development services in france and internationally. the company operates through five segments: france, united kingdom, other europe, sopra banking software, and other solutions. it offers digital transformation consulting services; technology services in the field of artificial intelligence, blockchain, cloud, data, internet of things, and intelligent process automation; systems integration comprising smart application modernisation and product lifecycle management; infrastructure management services, including consulting, managed and cloud, end-user support, digital workplace, and legacy services; and cybersecurity services. the company also provides property management solutions; banking solutions, including software, support, and associated consulting services to banks and financial institutions; and hr solutions to public and private sector organisations, as well as acts as a software house, integrator, advisor, and cloud player. in addition, it offers business process services, such as creation or on-boarding, and operation of multi-function shared services; and operation of finance and administration, and human resource functions, as well as operation of specialised industry-specific business processes comprising operating and executing services in police control rooms, managing compliance in financial services, and managing customer services for large utilities. it serves aerospace, defense and security, energy and utilities, financial services, insurance and social, government, retail, telecommunication, media and entertainment, and transport industries. sopra steria group sa was incorporated in 1968 and is headquartered in paris, france.

earnings per share

as for profitability, sopra steria group has a trailing twelve months eps of €12.11.

pe ratio

sopra steria group has a trailing twelve months price to earnings ratio of 16.42. meaning, the purchaser of the share is investing €16.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.77%.

volatility

sopra steria group's last week, last month's, and last quarter's current intraday variation average was a negative 0.78%, a negative 0.36%, and a positive 1.25%.

sopra steria group's highest amplitude of average volatility was 1.63% (last week), 1.57% (last month), and 1.25% (last quarter).

dividend yield

as claimed by morningstar, inc., the next dividend payment is on may 29, 2023, the estimated forward annual dividend rate is 4.3 and the estimated forward annual dividend yield is 2.34%.

more news about sopra steria group.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com